39. 中毒性表皮壊死症 Disease details / Clinical trials / Drug dev / DR info

臨床試験数 : 15 / 薬物数 : 16 - (DrugBank : 9) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 99

薬物、開発者（Primary Sponsor）、臨床試験情報（症例登録開始年（Enrollment year）、フェーズ、ID、実施国）
Abrocitinib
   Peng Zhang
      2023   Early Phase 1   NCT06119490   China
Adipose derived stromal cells intravenously injected
   Assistance Publique - Hôpitaux de Paris
      2022   Phase 1/Phase 2   NCT04711200   -
Clobetasol 0.05% ointment
   University of California, Davis
      2016   Phase 1/Phase 2   NCT02319616   United States
Etanercept
   Abe Riichirou
      2021   Phase 2   JPRN-jRCTs031210325   -
Etanercept 50 MG SC DAY 1 and DAY 4
   Vanderbilt University Medical Center
      2023   Phase 3   NCT02987257   United States
Harmonized supportive care
   Vanderbilt University Medical Center
      2023   Phase 3   NCT02987257   United States
Infliximab
   Loyola University
      2006   Phase 2   NCT00372723   United States
   Massachusetts Eye and Ear Infirmary
      2010   Phase 1/Phase 2   NCT01256489   United States
Intravenous immunoglobulin
   Nihon Pharmaceutical Co., Ltd
      2012   Phase 3   NCT01696500   Japan
Isotretinoin
   Massachusetts General Hospital
      2016   -   NCT02795143   United States
Methylprednisolone
   Morita Eishin
      2017   Phase 2   JPRN-jRCTs061180044   Germany;Japan;Taiwan
Palifermin
   Brett King
      2010   Phase 1/Phase 2   NCT02037347   United States
Prednisolone
   Morita Eishin
      2017   Phase 2   JPRN-jRCTs061180044   Germany;Japan;Taiwan
Recombinant granulocyte - colony stimulating factor
   University of Liege
      2016   Phase 4   NCT02739295   Belgium
Site specific standard OF care comparison
   Massachusetts General Hospital
      2024   -   NCT03585946   -
Tofacitinib
   Chang Gung Memorial Hospital
      2022   -   NCT06474078   Taiwan
   Peng Zhang
      2023   Early Phase 1   NCT06119490   China
Topical infliximab
   James Chodosh, MD, MPH
      2014   Phase 1/Phase 2   NCT02126020   Canada;United States